Combination of | |
---|---|
Salbutamol | Beta2-adrenergic agonist |
Budesonide | Corticosteroid |
Clinical data | |
Trade names | Airsupra |
Other names | PT027, albuterol/budesonide |
AHFS/ Drugs.com | Monograph |
License data | |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. [1] [2] It is a combination of salbutamol sulfate (albuterol sulfate), a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. [1] [2] It is inhaled using a pressurized metered-dose inhaler. [1] [2]
The most common side effects include headache, oral candidiasis, cough, and difficulty speaking. [2]
Salbutamol/budesonide was approved for medical use in the United States in January 2023. [2] [3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA). [2] It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma. [2]
Salbutamol/budesonide is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks. [1] [2]
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study. [2]
Combination of | |
---|---|
Salbutamol | Beta2-adrenergic agonist |
Budesonide | Corticosteroid |
Clinical data | |
Trade names | Airsupra |
Other names | PT027, albuterol/budesonide |
AHFS/ Drugs.com | Monograph |
License data | |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. [1] [2] It is a combination of salbutamol sulfate (albuterol sulfate), a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. [1] [2] It is inhaled using a pressurized metered-dose inhaler. [1] [2]
The most common side effects include headache, oral candidiasis, cough, and difficulty speaking. [2]
Salbutamol/budesonide was approved for medical use in the United States in January 2023. [2] [3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA). [2] It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma. [2]
Salbutamol/budesonide is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks. [1] [2]
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study. [2]